Intravitreal bevacizumab (avastin) as a treatment for refractory macular edema in patients with uveitis: A pilot study

Retina

Volumn 28, Issue 1, 2008, Pages 41-45

  Mackensen, Friederike ^a   Heinz, Carsten ^b   Becker, Matthias D ^a   Heiligenhaus, Arnd ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b ST FRANZISKUS HOSPITAL   (Germany)

Author keywords

Bevacizumab; Intravitreal injection; Macular edema; Uveitis

Indexed keywords

ACETAZOLAMIDE; BEVACIZUMAB; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; COMORBIDITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; PILOT STUDY; RETINA FOVEA; RETINA MACULA EDEMA; RETROSPECTIVE STUDY; THICKNESS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; UVEITIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 38049123471     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318156db75     Document Type: Article

References (17)

1. Rothova A, Suttorp-van Schulten M, Treffers F, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 1996;80:332-336.
2. Ziemssen F, Bartz-Schmidt KU, Grisanti S. [(Side) effects of VEGF inhibition]. Ophthalmologe 2006;103:484-492.
3. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
4. Fine HF, Baffi J, Reed GF, et al. Aqueous humor and plasma vascular endothelial growth factor in uveitis-associated cystoid macular edema. Am J Ophthalmol 2001;132:794-796.
5. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-335.
6. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to agerelated macular degeneration. Retina 2006;26:383-390.
7. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-516.
8. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3-19.
9. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001;29:2-6.
10. Jonas JB, Degenring RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005;112:593-598.
11. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:632 e1.
12. Rosenfeld PJ. Intravitreal avastin: the low cost alternative to Lucentis? Am J Ophthalmol 2006;142:141-143.
13. Gillies MC. What we don't know about avastin might hurt us. Arch Ophthalmol 2006;124:1478-1479.
14. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431.
15. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-1444.
16. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-881.
17. Genentech. Health care provider letter. 2007. Available at:http://www.gene.com/gene/products/information/pdf/healthcare-provider-letter. pdf.